UPDATE: Benchmark Raises PT to $7.50 on CryoLife
Benchmark raises its price target on Buy-rated CryoLife (NYSE: CRY) on robust outlook ahead.
Benchmark says, "Guidance for 2012 EPS was $0.14-$0.18 versus the $0.33 consensus and our $0.28 forecast. Excluding $0.12-$0.14 per share in fully-taxed Medafor litigation expense, we equate guidance to $0.26-$0.32 in earnings power. We increase our price target to $7.50, from $6.50, as our valuation basis shifts to 2013."
CRY closed at $5.98 a share on Thursday.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.